ArticleMolecular pharmacology2006
Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.
Article in Molecular pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology.Journal of xenobiotics · 2026Review
- The Interplay Between theInternational journal of molecular sciences · 2024Review
- Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.International journal of molecular sciences · 2021Article
- Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.Pharmacology research & perspectives · 2020Article
- LncRNA PLAC2 down-regulates RPL36 expression and blocks cell cycle progression in glioma through a mechanism involving STAT1.Journal of cellular and molecular medicine · 2018Article
- Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells.International journal of molecular sciences · 2017Article
- Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control.Scientific reports · 2016Article
- Article
- Cisplatin in cancer therapy: molecular mechanisms of action.European journal of pharmacology · 2014Review
- Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.Pharmacogenomics · 2014Review
- Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.Pharmacological reviews · 2012Review
- Identification and validation of protein targets of bioactive small molecules.Bioorganic & medicinal chemistry · 2012Review
- Lowly expressed ribosomal protein s19 in the feces of patients with colorectal cancer.ISRN gastroenterology · 2012Article
- Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.Journal of cellular physiology · 2010Article
- Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer.Journal of cellular and molecular medicine · 2008Article
- A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Based on analyses of two-dimensional gel and cDNA microarrays, our laboratory and others have demonstrated that a number of genes show altered expression during the development of cisplatin resistance (CP-r) in human cancer cells, including genes associated with DNA damage repair, proto-oncogenes, apoptosis, stress-response, and transcription factors. To verify these results and find genes that are directly responsible for CP-r, as opposed to those reflecting a secondary response induced by cisplatin treatment or resulting from CP-r, we constructed a retroviral cDNA library in the vector pLNCX2 from KB-CP.5 (KCP.5), a cell line selected in one step after exposure to cisplatin at 0.5 microg/ml. Using a library of cDNAs (1.8 x 10(6) cDNA clones) and an intermittent cisplatin selection system to allow more effective functional cloning, 11 expressed cDNAs were identified in a primary pool of 93,000 transfected cell clones. Metallothionein 2A, a known CP-r gene, was among these 11 genes found in the transfectants after CP selection. Several other genes, including those encoding ribosomal proteins (e.g., RPL36) and heat shock protein (e.g., HSP10), were also found among the cisplatin-selected clones. Transfection of either the RPL36 cDNA or HSP10 cDNA conferred on KB-3-1 cells 2.5- to 3-fold resistance to cisplatin by clonogenic assays. A subsequent transfection also identified RPL36 as a CP-r gene. The finding that a ribosomal protein gene, RPL36, contributes to CP-r should stimulate study of the role of ribosomal proteins in multifactorial mechanisms of cisplatin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.